Get access

Analysis and Quantitation of the β-Amyloid Precursor Protein in the Cerebrospinal Fluid of Alzheimer's Disease Patients with a Monoclonal Antibody-Based Immunoassay


  • The present address of Dr. T. Henriksson is Cetus Corporation, 1400 Fifty-Third Street, Emeryville, CA 94608, U.S.A.

Address correspondence and reprint requests to Dr. D. B. Schenk at Athena Neurosciences, Inc., 800-F Gateway Boulevard, South San Francisco, CA 94080, U.S.A.


Abstract: One of the major clinical findings in Alzheimer's disease (AD) is the formation of deposits of β-amyloid protein in amyloid plaques, derived from the β-amyloid precursor protein (β-APP). To determine the possible use of β-APP as a diagnostic marker for AD in CSF, a monoclonal antibody-based immunoassay specific for this protein was developed. The assay does not differentiate between β-APP695 and β-APP751 forms but does preferentially recognize β-APP751 complexed with a protease. Of the two sets of CSF samples tested, one set, obtained from living patients, gave a slightly lower level of β-APP in AD and Parkinson's disease patients relative to controls, whereas the other set, composed of postmortem samples, showed no significant differences between the AD and control groups.

Get access to the full text of this article